<DOC>
	<DOC>NCT00994513</DOC>
	<brief_summary>The major objective of this study is to conduct a double-blind, placebo-controlled, randomized clinical trial to assess whether oral alpha lipoic acid supplementation will decrease cardiovascular disease and type 2 diabetes risk in obese subjects.</brief_summary>
	<brief_title>Effect of Alpha Lipoic Acid on Obesity Related Comorbidities</brief_title>
	<detailed_description />
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Thioctic Acid</mesh_term>
	<criteria>Han ethnicity BMI≥25kg/m2 Having at least one of the following risk factors: borderline hypertension (130mmHg≤SBP&lt;140mmHg or 85mmHg≤DBP&lt;90mmHg), dyslipidemia (fasting total cholesterol ≥240mg/dl or HDLC&lt;40mg/dl), or impaired fasting glucose (fasting glucose levels between 6.1 and 7.0mmol/L) 1860 years old Not on any antioxidant vitamin supplement Pregnancy, lactation or childbearing age without birth control device History of hypertension, diabetes, coronary heart disease(CHD), cancer or liver disease Anything that would impede the subject from complying with the ALA treatment History of psychiatric problems</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Antioxidant</keyword>
	<keyword>Obesity</keyword>
</DOC>